Evidence map›Paper›PMID 41971943›Full record

ArticleComputational and structural biotechnology journal2026

Computational Approach Improves Diagnostic Performance Based on Tumor-Associated Autoantibodies in Esophageal Squamous Cell Carcinoma.

Yosui Nojima, Fumiaki Shiratori, Takashi Suzuki, Satoshi Yajima, Takeshi Toyozumi, Hideaki Shimada

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yosui NojimaCenter for Mathematical Modeling and Data Science, The University of Osaka, Toyonaka, Osaka 560-8531, Japan.ORCID https://orcid.org/0000-0002-6821-0093
Fumiaki ShiratoriDepartment of Surgery, School of Medicine, Toho University, Ota-ku, Tokyo 143-8541, Japan.
Takashi SuzukiDepartment of Surgery, School of Medicine, Toho University, Ota-ku, Tokyo 143-8541, Japan.
Satoshi YajimaDepartment of Surgery, School of Medicine, Toho University, Ota-ku, Tokyo 143-8541, Japan.
Takeshi ToyozumiDepartment of Frontier Surgery, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba 260-8677, Japan.ORCID https://orcid.org/0000-0002-0939-3299
Hideaki ShimadaDepartment of Surgery, School of Medicine, Toho University, Ota-ku, Tokyo 143-8541, Japan.ORCID https://orcid.org/0000-0002-1990-8217

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although tumor-associated autoantibodies (TAAbs) are promising biomarkers for early cancer detection, the diagnostic performance of individual TAAbs for esophageal squamous cell carcinoma (ESCC) remains limited. In this study, we constructed machine learning (ML) models for ESCC diagnosis using the serum levels of 6 TAAbs (c-myc, NY-ESO-1, p53, p62, RalA, and Sui1) and compared their performance with that of a conventional approach. When the training and test datasets were combined, serum samples from 339 patients with ESCC and 152 healthy controls were analyzed. To address class imbalance, the training data were oversampled using the synthetic minority oversampling technique. Classification models were developed using 5 ML algorithms, among which the svmLinear (support vector machine with a linear kernel), svmRadial (support vector machines with a radial basis function kernel), and neural network models demonstrated robust performance without overfitting. At specificities exceeding 90%, these models achieved substantially higher sensitivities than those obtained using any single TAAb. Notably, the svmLinear and neural network models achieved sensitivities greater than 40% for early-stage ESCC (stage 0/I) in the test dataset. Overall, the integration of multiple TAAbs with ML substantially improved the diagnostic performance for ESCC, highlighting the clinical potential of ML-based approaches.

Identifiers

PMID41971943
PMCPMC13068007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.